Drugs / RiaSTAP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03304899 | Oct 2018 → Dec 2019 | hemorrhagic disease, traumatic brain injury | Leila Dehghani | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01910675 | Jul 2013 → Oct 2018 | — | Helsinki University Central Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT01300286 | Dec 2010 → Dec 2012 | hemorrhagic disease | Duke University | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT05780125 Comparator | Mar 2023 → Feb 2024 | coagulation protein disease, heart disorder, hemorrhagic disease | IRCCS Policlinico S. Donato | Completed | Missed primary |
| Phase 4 | NCT02822599 Comparator | Jun 2017 → Aug 2019 | coagulation protein disease, hemorrhagic disease | Nicklaus Children's Hospital f/k/a Miami Children's Hospital | Completed | No outcome recorded |
| — | NCT02540434 Comparator | Oct 2015 → Jul 2016 | blood coagulation disease | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Enrollment |
Press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RiaStAP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02822599 ↗ |
| Known as | Fibrinogen Concentrate (Human) | “RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.” NCT03304899 ↗ |
| Action | Restore | “fibrinogen replacement” NCT02540434 ↗ |
| Modality | Protein / enzyme biologic | “fibrinogen concentrate (RiaSTAP, CSL Behring, Marburg, Germany)” NCT01300286 ↗ |
| Route | Intravenous | “administered intravenously” NCT01300286 ↗ |